Unknown

Dataset Information

0

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates.


ABSTRACT: The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate.

SUBMITTER: Pan X 

PROVIDER: S-EPMC8423076 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8703211 | biostudies-literature
| S-EPMC4441047 | biostudies-literature
| S-EPMC7921634 | biostudies-literature
| S-EPMC8727235 | biostudies-literature
| S-EPMC7536651 | biostudies-literature
| S-EPMC10893453 | biostudies-literature
| S-EPMC5853543 | biostudies-literature
| S-EPMC2669169 | biostudies-other
| S-EPMC3964096 | biostudies-literature
| S-EPMC4444235 | biostudies-literature